Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Bile Duct Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Venous Thromboembolism 1Supratentorial Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sigmoid Neoplasms 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Glioma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Erectile Dysfunction 1Endometrial Neoplasms 1Dyskinesias 1Diarrhea 1Chemotherapy-Induced Febrile Neutropenia 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 160Fluorouracil 134Paclitaxel 125Radiotherapy 117Oxaliplatin 87Carboplatin 71Docetaxel 70Irinotecan 59pembrolizumab 57Capecitabine 57Leucovorin 56Radiation 47Surgical Procedures, Operative 33Drug Therapy 33Esophagectomy 31Cetuximab 25Neoadjuvant Therapy 24Nivolumab 23Bevacizumab 21Trastuzumab 20camrelizumab 19S 1 (combination) 19Chemoradiotherapy 17Albumin-Bound Paclitaxel 16Magnetic Resonance Spectroscopy 15Epirubicin 15tislelizumab 14Taxes 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Esophageal Neoplasms × Long-Term Synaptic Depression × Clear all
NCT05637268 2022-12-05

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
23 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡